Several reports indicate that progranulin promotes resistance to platinum-based chemotherapy agents in various cancer types, including ovarian [139], colorectal [140], hepatocellular [141] and bladder cancer [142]. The gene discussed is GRN; the disease is urinary bladder cancer.